EP0937089A1 - Neue knoevenagel-kondensationsprodukte, verfahren zu deren herstellung und verwendung - Google Patents
Neue knoevenagel-kondensationsprodukte, verfahren zu deren herstellung und verwendungInfo
- Publication number
- EP0937089A1 EP0937089A1 EP97951145A EP97951145A EP0937089A1 EP 0937089 A1 EP0937089 A1 EP 0937089A1 EP 97951145 A EP97951145 A EP 97951145A EP 97951145 A EP97951145 A EP 97951145A EP 0937089 A1 EP0937089 A1 EP 0937089A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- compounds according
- compounds
- treatment
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims abstract description 9
- 238000006000 Knoevenagel condensation reaction Methods 0.000 title claims abstract description 8
- 239000007859 condensation product Substances 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- -1 pyridoxylidene rhodanine Chemical compound 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- WJDPAGLWZIPYMX-WAPJZHGLSA-N [5-hydroxy-6-methyl-4-[(z)-(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]pyridin-3-yl]methyl dihydrogen phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(\C=C/2C(NC(=S)S\2)=O)=C1O WJDPAGLWZIPYMX-WAPJZHGLSA-N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical compound O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 4
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 4
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 238000006911 enzymatic reaction Methods 0.000 claims description 3
- 230000004060 metabolic process Effects 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 241000709715 Hepatovirus Species 0.000 claims description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 2
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 229940126214 compound 3 Drugs 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 108020004682 Single-Stranded DNA Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- CEEQUQSGVRRXQI-UHFFFAOYSA-N Pyridoxal 5-phosphate monohydrate Chemical compound O.CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O CEEQUQSGVRRXQI-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000695 excitation spectrum Methods 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- XRCNLLJRVWMRCX-UHFFFAOYSA-N 2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound O=C1CSC(=S)N1.O=C1CSC(=S)N1 XRCNLLJRVWMRCX-UHFFFAOYSA-N 0.000 description 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 1
- 238000004679 31P NMR spectroscopy Methods 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- GGONJYSEALVEMH-WENINEFDSA-N [5-hydroxy-6-methyl-4-[(z)-(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]pyridin-3-yl]methyl dihydrogen phosphate;sodium Chemical compound [Na].CC1=NC=C(COP(O)(O)=O)C(\C=C/2C(NC(=S)S\2)=O)=C1O GGONJYSEALVEMH-WENINEFDSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003223 pyridoxals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000001758 scanning near-field microscopy Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000000363 spectroscopic quantification Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
- 238000012982 x-ray structure analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Definitions
- the present invention relates to new Knoevenagel condensation products, processes for their production and their use, in particular for pharmaceutical and analytical purposes. Furthermore, conjugates of the Knoevenagel condensates with biomolecules are disclosed.
- the problem underlying the present invention was to provide new compounds which can be used in particular for pharmaceutical and analytical purposes.
- This object is achieved by the synthesis of the compound (Z) -5'-O-phosphonopyridoxidenidhhodanin (3), which is a derivative of the vitamin B6 coenzyme pyridoxal-5'-phosphate (1).
- Compound (3) is prepared by reacting (1) with the synthetic heterocyclic compound rhodanine (2) in a Knoevenagel condensation (cf. also Kesel et al., Tetrahedron 52 (1 8.1 1 .1 996), 14787-14800).
- Compound 3 is named (Z) -5 - [[5-hydroxy-6-methyl-3- [(phosphonooxy) methyl] -4-pyridinyl] methylene] -2-thioxo-4-thiazolidinone.
- the rhodanine portion of this molecule is able to bind to biomolecules such as single-stranded nucleic acids.
- the charged phosphate group ensures good water solubility.
- Compound 3 is subject to a (Z / E) stereoisomerism to form the (E) isomer 4. This cis / trans rearrangement is triggered, for example, by UV radiation with the wavelengths 254 nm and / or 366 nm.
- red 3-pyridinolate 5 in the form of a free acid, e.g. in pyridine or dimethyl sulfoxide (DMSO).
- the yellow compound 3 forms a deep red monosodium salt, the structure of which could be elucidated by X-ray structure analysis. It was crystallized as hemiheptadecahydrate (8.5 hydrate) and is present as (Z) - stereoisomer 6. When exposed to UV radiation, the monosodium salt 6 is also subject to the cis / trans rearrangement to the red (E) stereoisomer 7.
- Derivatives of compound 3 can be obtained by reaction with C 12 -C 18 fatty acid chlorides on the OH group.
- the present invention further relates to compounds of the general formula (8).
- X 1 , X 2 and X 3 are each independently selected from O, S and NR 5 ;
- R ⁇ R 2 , R 3 , R 4 and R 5 are each independently selected from any substituent;
- R 6 is selected from optionally substituted hydrocarbon radicals and O and n is 0 or 1; and salts, for example salts with alkali metal, alkaline earth metal or ammonium ions, hydrates and stereoisomers thereof, with the proviso that the compound is not pyridoxylidene rhodanine.
- X 1 is preferably O.
- X 2 is preferably NR 5 , where R 5 is hydrogen or CC 4 alkyl and particularly preferably hydrogen.
- X 3 is preferably S.
- Y is preferably S.
- Z is preferably CR 5 , where R 5 is hydrogen or C r C 4 alkyl and particularly preferably hydrogen.
- the substituents R 1 to R 4 can in themselves be any substituents provided that they are compatible with the overall structure.
- R 1 and R 2 or / and R 3 and R 4 can be bridged.
- the substituents R 1 to R 4 are hydrogen, halogen, hydroxyl, amine and optionally substituted alkyl radicals, for example C to C 6 alkyl, aminoalkyl, hydroxyalkyl, alkoxy etc.
- at least one of the substituents R to R 4 contains a sub physiologically negatively charged group, for example an acid group such as phosphate, carboxylate, sulfonate etc.
- the compounds of the general formula (8) are particularly preferably the (Z) -5-O-phosphonopyridoxylidene rhodanine (3), and salts, hydrates and stereoisomers thereof.
- the present invention further provides a process for the preparation of a compound of the general formula (8), characterized in that a compound of the formula (9)
- REPLACEMENT BUTT (RULE 26) wherein X 1 , X 2 , X 3 , Y, Z, R 1 -R 5 and R 6 are as defined for the compounds 8.
- the reaction is preferably carried out in an essentially equimolar ratio of 9 to 10 in a suitable solvent or solvent mixture.
- the temperature is preferably from room temperature to the reflux temperature of the solvent.
- the compounds of general formula (8) surprisingly have pharmaceutical activity.
- the invention thus furthermore relates to a pharmaceutical composition which contains as active ingredient a compound as stated above (preferably without taking into account the disclaimer in claim 1) and, if appropriate, pharmaceutically customary additives, auxiliaries, carriers and diluents.
- a first important application of the compounds according to the invention is the treatment of infectious diseases, for example viral infections, parasitic diseases, fungal diseases or bacterial diseases.
- infectious diseases for example viral infections, parasitic diseases, fungal diseases or bacterial diseases.
- viral infections in particular those viral infections which are caused by enveloped viruses, such as hepadnaviruses, herpes viruses or retroviruses, e.g. HIV.
- enveloped viruses such as hepadnaviruses, herpes viruses or retroviruses, e.g. HIV.
- the compounds according to the invention have also proven suitable for the treatment of diseases which are caused by other viruses, such as, for example, influenza or papilloma viruses.
- the compounds according to the invention have proven to be very suitable for controlling parasites such as, for example, Leishmania, Plasmodia or Trypanosomes.
- the compounds are most preferably used in HIV therapy, for example in combination therapy with other agents such as AZT or DDI.
- the compounds according to the invention are also used to combat tumor diseases, for example leukemia, in particular T-cell leukemia, or skin tumors such as malignant tumors.
- tumor diseases for example leukemia, in particular T-cell leukemia, or skin tumors such as malignant
- the compounds 8 also have immunomodulatory effects and are therefore suitable, for example, for the treatment of autoimmune diseases such as, for example, multiple sclerosis, Alzheimer's disease, lupus erythematosus, myasthenia gravis, chronic arthritis, type I diabetes, etc. and various neurodegenerative diseases.
- autoimmune diseases such as, for example, multiple sclerosis, Alzheimer's disease, lupus erythematosus, myasthenia gravis, chronic arthritis, type I diabetes, etc. and various neurodegenerative diseases.
- the compounds 8 are suitable for the treatment of diseases which exist in connection with disorders of the vitamin B metabolism, e.g. as a vitamin B6 antagonist.
- the compounds of the invention act as effectors, e.g. Activators, inhibitors or modifiers, on enzymatic reactions of the caspase system, and in particular as inhibitors of nitrogen monoxide synthases.
- compounds 8 can influence the secretion of TNF ⁇ in T lymphocytes. They are also able to bind to the cellular CD38 receptor, thereby inhibiting the binding of HIV gp41. In this way, the signal transmission path is decoupled from CD38, which leads to an inhibition of syncytia formation, NO release, T cell death by apoptosis, and single cell lysis.
- the compounds according to the invention can be used as such for therapeutic purposes. However, they can also be used as chelates with polyvalent metal ions or as noncovalent and / or covalent conjugates with biomolecules, for example nucleic acids, proteins, lipids, fatty acids etc.
- the pharmaceutical compositions according to the invention can be in any form, for example as creams, ointments, injectable or orally administrable liquids, liposomal formulations, tablets, dragées, capsules etc.
- the application can be, for example, locally or systemically, topically, orally or by injection.
- the dosage can be varied within a wide range, for example from 0.01 ⁇ g to 1 mg per kg of body weight, depending on the type of disease and application.
- the compounds according to the invention are also suitable as detection reagents.
- they can be used in the form of radioactive, for example with 3 H, 14 C, 32 P or 35 S-labeled derivatives.
- use in unlabelled form is preferred, since its strong coloring or fluorescent properties make it easy to detect in biological systems.
- the compounds according to the invention are therefore suitable for the detection of biomolecules, for example in diagnostic analysis methods, for example for the detection of single-stranded nucleic acids.
- the compounds are also suitable for structure elucidation, for example for sequencing proteins or nucleic acids.
- the compounds according to the invention can also be used for electrochromic applications, e.g. can be used as molecular digital switch substances or indicators for pH value, temperature and solvent.
- the compounds or derivatives thereof according to the invention are suitable as absorbers for ions, organic substances etc. or due to their intense colors and reversible color changes for decorative applications.
- the alkaline earth metal salts for example Mg or Ca salts of the compounds, which are in the form of gels.
- nanotechnology where, for example, individual fluorescent dye molecules and biomolecule derivatives excited with laser systems are detected and detected by sensitive detection systems, for example CCD cameras or avalanche detectors and optical techniques on thin-layer plates, in membranes, cells, drops, capillaries, etc. can be located.
- sensitive detection systems for example CCD cameras or avalanche detectors and optical techniques on thin-layer plates, in membranes, cells, drops, capillaries, etc.
- Further possibilities for single-molecule localization are optical scanning near-field microscopy on mini chips, confocal microscopy in polyacrylamide gels, for example 2-dimensional or multidimensional gel electophoresis of nucleic acids.
- the present invention also relates to derivatives of the compounds (8) which result from hydrolytic degradation and have, for example, the general formulas 11, 12 or 13:
- Fig. 1 the protection of cells against HIV infection mediated by compound (3).
- Fig.2 a schematic representation of hydrolysis by-products that arise during the synthesis of compound (3)
- REPLACEMENT BUTT (RULE 26) The mixture is boiled on a water bath with stirring under reflux. The pyridoxal-5'-phosphate monohydrate now slowly goes into solution and an initially yellow, then orange, then red suspension is formed. After boiling for 20 minutes, 1 50 ml of water are added through the cooler because the suspension begins to belch. The mixture is heated for a further 10 min, during which the red reaction product precipitates and leads to belching. Then refrigerate in the freezer at a temperature of - 18 ° C for no more than 2 hours.
- the orange product is filtered off, transferred with the mother liquor and with 100 ml of ice-cold abs. Washed ethanol. Vacuum drying in a desiccator over anhydrous calcium chloride; Yield: 9.85 g of orange-yellow crude product (Z) -5 - [[5-hydroxy-6-methyl-3- [phosphonooxy) methyl] -4-pyridinyl] - methylene] -2-thioxo-4-thiazolidinone.
- the product contains educts, by-products and, despite vacuum drying, ethanol and water.
- the analysis of compound 3 comprises 1 H-NMR spectroscopy, 13 C-NMR spectroscopy, 31 P-NMR spectroscopy, RP-18 HPLC, fast atom bombardment mass spectrometry (FAB MS), IR spectroscopy, UV spectrophotometry and fluorescence spectrophotometry. Typical analytical data of compound 3 follow.
- Compounds 3 and 6 can be used in radiolabelled form, for example labeled with 3 H, 14 C, 32 P or 35 S, as probes for the detection of single-stranded nucleic acids.
- the substances 3/6 can also be used for the fluorescence detection of single-stranded DNA.
- the (E) stereoisomer 4 fluoresces in DSMO, the (Z) stereoisomer in water significantly less.
- the (E) stereoisomer 4 is bound to single-stranded DNA, single-stranded DNA can be detected when fluorescence occurs after extraction with DMSO.
- the wavelength used for excitation is in the range from 420 to 500 nm, the emission in DMSO or pyridine is 575 nm.
- Substance 6 inhibits the neuronal, endothelial and immunologically / - inducible isoforms of nitrogen monoxide synthase (NOS).
- the inhibition constant (IC 50 ) for nNOS is 61.25 ⁇ M.
- the inhibition constant (IC 50 ) is 50 ⁇ M.
- Substance 3 can be used in radioactively labeled or unlabelled form for the two-dimensional electrophoretic separation of single-stranded nucleic acids. In the first dimension there can be a separation according to the charge and in the second dimension a separation according to the molecular size. Compound 3 can be associatively or covalently coupled to the nucleic acid.
- Substance 3 and derivatives thereof are effective as therapeutic agents, in particular for influencing the propagation processes of infectious agents, e.g. from those that occur in the host with intermediates as single-stranded DNA, such as retroviruses, herpes viruses or hepatoviruses.
- Myeloid HUT78 cells are exposed to HIV infection in the absence or in the presence of 1, 87 mM or 0, 1 87 mM compound 3.
- the HIV detection is carried out by photometric determination of the p24 antigen. From Figure 1 it can be seen that no p24 was detectable in the cells treated according to the invention, whereas in the control the p24 test was positive from the seventh day.
- Total remission is found a few hours after local application to the affected skin.
- a patient (51 years, male) with virus flu is orally treated with a few drops of an H 2 O / DMSO solution of compound 3 (approx. 1 ⁇ g / ml). The disease symptoms disappeared overnight.
- the (Z / E) stereoisomerism of compound 3 occurs depending on the temperature (thermochromism) and depending on the solvent (solvatochromism). 3 can therefore be used as a temperature indicator and / or solvent indicator.
- the (Z / E) stereoisomerism of compounds 3 and 4 occurs depending on the application of an electric field (electrochromism). Therefore 3 can be used as a digital switching element due to the different fluorescence spectroscopic properties compared to 4 e.g. when excited by laser light with a wavelength of 480 nm. Thereby, after applying an electric field to 3, rearrangement in 4 occurs and thus fluorescence emission up to 575 nm after excitation at 480 nm.
- Compound 3 can act in metabolism as an antagonist of the coenzyme pyridoxal-5'-phosphate by binding to the enzymes which require this coenzyme and therefore have tumor-inhibiting properties. - 1 7 -
- Compound 3 can be used for the proliferation control / chemotherapy / cytostatic therapy of malignant tumors in local application to skin tumors (malignant melanoma, Karposi sarcoma), possibly in combination with UV radiation, and / or for the proliferation control of other skin diseases with an increased cell division rate (e.g. Psoriaris) can be used.
- the binding of compound 3 to replication-active single-stranded DNA regions can be photochemically fixed by UV radiation and leads to locally limited cytotoxicity.
- Compound 3 due to its coloring and fluorescent properties, as well as its ability to couple to biomolecules, e.g. Proteins are used for structure elucidation, e.g. for amino acid sequence determination of proteins or for DNA sequencing.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polyesters Or Polycarbonates (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19645974 | 1996-11-07 | ||
DE19645974A DE19645974C1 (de) | 1996-11-07 | 1996-11-07 | (Z)-5-[[3-Hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methylen]-2-thioxo-4- thiazolidinon, Verfahren zu dessen Herstellung und Verwendung |
PCT/EP1997/006184 WO1998020013A1 (de) | 1996-11-07 | 1997-11-07 | Neue knoevenagel-kondensationsprodukte, verfahren zu deren herstellung und verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0937089A1 true EP0937089A1 (de) | 1999-08-25 |
Family
ID=7810958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97951145A Withdrawn EP0937089A1 (de) | 1996-11-07 | 1997-11-07 | Neue knoevenagel-kondensationsprodukte, verfahren zu deren herstellung und verwendung |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0937089A1 (de) |
JP (1) | JP2001503752A (de) |
KR (1) | KR20000053141A (de) |
CN (1) | CN1236369A (de) |
AU (1) | AU728345B2 (de) |
BR (1) | BR9712930A (de) |
CA (1) | CA2270973A1 (de) |
CZ (1) | CZ160999A3 (de) |
DE (1) | DE19645974C1 (de) |
HU (1) | HUP9904289A3 (de) |
IL (1) | IL129826A0 (de) |
NO (1) | NO992209L (de) |
NZ (1) | NZ335977A (de) |
PL (1) | PL333128A1 (de) |
SK (1) | SK61799A3 (de) |
TR (1) | TR199901733T2 (de) |
WO (1) | WO1998020013A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL139376A0 (en) * | 1998-05-04 | 2001-11-25 | Monomeric, oligomeric and polymeric knoevenagel condensation products | |
BR9913157A (pt) * | 1998-08-21 | 2001-05-15 | Viropharma Inc | Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto |
RU2001132323A (ru) * | 1999-04-30 | 2004-02-20 | Вальтер ОБЕРТЮР (DE) | Антиокислительные аналоги витамина B6 |
US20030071780A1 (en) * | 2001-10-16 | 2003-04-17 | Vincent Kent D. | High resolution display |
US6940497B2 (en) | 2001-10-16 | 2005-09-06 | Hewlett-Packard Development Company, L.P. | Portable electronic reading apparatus |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9103776D0 (sv) * | 1991-12-19 | 1991-12-19 | Astra Ab | New compounds |
IT1266570B1 (it) * | 1993-07-30 | 1997-01-09 | Zambon Spa | Derivati della propanammide n-eteroaril sostituiti utili nel trattamento delle malattie cardiovascolari |
FR2722790B1 (fr) * | 1994-07-19 | 1996-10-04 | Roussel Uclaf | Nouvelles cephalosporines comportant en position 7 un radical benzyloxymino subtitue, leur procede de preparation leur application comme medicaments |
-
1996
- 1996-11-07 DE DE19645974A patent/DE19645974C1/de not_active Expired - Fee Related
-
1997
- 1997-11-07 WO PCT/EP1997/006184 patent/WO1998020013A1/de not_active Application Discontinuation
- 1997-11-07 NZ NZ335977A patent/NZ335977A/xx unknown
- 1997-11-07 KR KR1019990704073A patent/KR20000053141A/ko not_active Application Discontinuation
- 1997-11-07 PL PL97333128A patent/PL333128A1/xx unknown
- 1997-11-07 CZ CZ991609A patent/CZ160999A3/cs unknown
- 1997-11-07 TR TR1999/01733T patent/TR199901733T2/xx unknown
- 1997-11-07 AU AU54798/98A patent/AU728345B2/en not_active Revoked
- 1997-11-07 BR BRPI9712930-5A patent/BR9712930A/pt not_active IP Right Cessation
- 1997-11-07 CA CA002270973A patent/CA2270973A1/en not_active Withdrawn
- 1997-11-07 SK SK617-99A patent/SK61799A3/sk unknown
- 1997-11-07 EP EP97951145A patent/EP0937089A1/de not_active Withdrawn
- 1997-11-07 CN CN97199496A patent/CN1236369A/zh active Pending
- 1997-11-07 HU HU9904289A patent/HUP9904289A3/hu unknown
- 1997-11-07 JP JP52107198A patent/JP2001503752A/ja active Pending
- 1997-11-07 IL IL12982697A patent/IL129826A0/xx unknown
-
1999
- 1999-05-06 NO NO992209A patent/NO992209L/no not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9820013A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1998020013A1 (de) | 1998-05-14 |
CZ160999A3 (cs) | 1999-09-15 |
AU728345B2 (en) | 2001-01-04 |
KR20000053141A (ko) | 2000-08-25 |
SK61799A3 (en) | 2000-01-18 |
JP2001503752A (ja) | 2001-03-21 |
HUP9904289A2 (hu) | 2001-04-28 |
CN1236369A (zh) | 1999-11-24 |
TR199901733T2 (xx) | 1999-09-21 |
NZ335977A (en) | 2000-12-22 |
PL333128A1 (en) | 1999-11-22 |
DE19645974C1 (de) | 1998-08-13 |
NO992209L (no) | 1999-07-01 |
NO992209D0 (no) | 1999-05-06 |
BR9712930A (pt) | 2006-04-18 |
CA2270973A1 (en) | 1998-05-14 |
HUP9904289A3 (en) | 2001-08-28 |
IL129826A0 (en) | 2000-02-29 |
AU5479898A (en) | 1998-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69029212T2 (de) | 4-Amino-1H-Imidazo(4,5-c)chinoline als antivirale Mittel | |
DE69011914T2 (de) | Olefinisch substitierte 1H-Imidazo[4,5-c]chinolin-4-amine. | |
DE68906183T2 (de) | 2'-desoxy-5-fluoruridinderivate. | |
DE69522490T2 (de) | Platinkomplexe | |
DE2815724A1 (de) | Indolderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
EP0313874B1 (de) | Dischwefel-Analoge von LL-E33288 Antitumor-Verbindungen | |
DE69218042T2 (de) | Aromatische Amid-Verbindungen und ihre Herstellung und Anwendung | |
EP0901501B1 (de) | Nucleosid-derivate mit photolabilen schutzgruppen | |
WO1998039334A1 (en) | Dna glycosylase inhibitors, and uses related thereto | |
DE2424119A1 (de) | Mycophenolsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel | |
Iyengar et al. | Preparation and antitumor activity of 7-substituted 1, 2-aziridinomitosenes | |
DE3413489C2 (de) | ||
WO1998020013A1 (de) | Neue knoevenagel-kondensationsprodukte, verfahren zu deren herstellung und verwendung | |
WO1998020013A9 (de) | Neue knoevenagel-kondensationsprodukte, verfahren zu deren herstellung und verwendung | |
Jaycox et al. | Potential DNA bis‐intercalating agents: Synthesis and antitumor activity of novel, conformationally restricted bis (9‐aminoacridines) | |
DE69128788T2 (de) | 1,2-dihydro-3h-dibenzoisochinolin-1,3-dione als antitumormittel | |
WO2004081023A1 (en) | Solubilization method of water-insoluble curcumin | |
HU193339B (en) | Process for producing amino-anthracene-dion-platinum-complexes | |
CN114656453A (zh) | 七甲川吲哚花菁-tempo化学偶链小分子和制备方法及其制备辐射防护制剂的应用 | |
EP0521353B1 (de) | Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung | |
DE2729165C2 (de) | Phenäthylaminderivate und deren Salze, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
DE69719071T2 (de) | Phenanthridiniumderivate | |
US11479570B2 (en) | Pentafluorophosphate derivative, its uses and an appropriate manufacturing method | |
Murdock et al. | N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity | |
EP1758904B1 (de) | Flavopereirinderivate zur krebstherapie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990531 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 19990531;LV PAYMENT 19990531;RO PAYMENT 19990531;SI PAYMENT 19990531 |
|
17Q | First examination report despatched |
Effective date: 20010611 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20030122 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1022698 Country of ref document: HK |